Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

NCT02597868 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT02597868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02597868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
Lead sponsor
Zhejiang Cancer Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 31, 2013
Completion date
July 31, 2017
Enrollment
132 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer